Lakshmanan Krishnamurti
Overview
Explore the profile of Lakshmanan Krishnamurti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kassim A, Walters M, Eapen M, Smith M, Logan B, Solh M, et al.
NEJM Evid
. 2025 Feb;
4(3):EVIDoa2400192.
PMID: 39998298
Background: Related human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with posttransplant cyclophosphamide may be curative for sickle cell disease. However, graft failure, severe graft-versus-host disease (GVHD), infections, and mortality...
2.
Shenoy S, Kanter J, Kassim A, Fitzhugh C, Stenger E, Bhatia M, et al.
Blood Adv
. 2025 Feb;
PMID: 39993235
An increasing number of allogeneic transplant and autologous gene modification transplant therapies seek to eradicate sickle hemoglobin and the consequent hemolysis, vasculopathy, functional compromise, morbidity and mortality. As these modalities...
3.
Gupta K, Krishnamurti L, Jain D
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):1-9.
PMID: 39644008
India, the most populous nation in the world, also has a high frequency of the sickle hemoglobin (HbS) allele globally. The Arab Indian HbS haplotype in India is characterized by...
4.
Gupta V, Krishnamurti L
Lancet Haematol
. 2024 Oct;
11(11):e812-e813.
PMID: 39482019
No abstract available.
5.
Walters M, Eapen M, Liu Y, El Rassi F, Waller E, Levine J, et al.
Blood Adv
. 2024 Oct;
9(5):955-965.
PMID: 39471440
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment...
6.
Lessard S, Rimmele P, Ling H, Moran K, Vieira B, Lin Y, et al.
Sci Rep
. 2024 Oct;
14(1):24298.
PMID: 39414860
BIVV003 is a gene-edited autologous cell therapy in clinical development for the potential treatment of sickle cell disease (SCD). Hematopoietic stem cells (HSC) are genetically modified with mRNA encoding zinc...
7.
Arnold S, Bakshi N, Ross D, Smith C, Sinha C, Veludhandi A, et al.
Am J Hematol
. 2024 Aug;
99(10):2037-2040.
PMID: 39105410
We prospectively collected PROMIS©25 and PROMIS©29 surveys in the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR). Mobility and social participation T-scores were decreased; all other...
8.
George S, Veludhandi A, Xiang Y, Liu K, Stenger E, Arnold S, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):912.e1-912.e13.
PMID: 38972510
Conditioning regimens for hematopoietic cell transplant (HCT) in patients with sickle cell disease (SCD) place patients at risk for reproductive health issues. The purpose of this study was to assess...
9.
Jagtiani A, Chou E, Gillespie S, Liu K, Krishnamurti L, McClish D, et al.
Pain
. 2024 May;
165(10):2364-2369.
PMID: 38787626
The US National Pain Strategy recommends identifying individuals with chronic pain (CP) who experience substantial restriction in work, social, or self-care activities as having high-impact chronic pain (HICP). High-impact chronic...
10.
Jain D, Gupta M, Madkaikar M, Jena R, Khargekar N, Saraf S, et al.
Lancet Haematol
. 2024 May;
11(5):e322-e323.
PMID: 38701819
No abstract available.